BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

xStep raises funding from Titan Capital to scale non-invasive neurorehabilitation platform

01 September 2026 | News

xStep plans to build up its manufacturing, expand clinical collaborations in India and abroad

xStep, a Bengaluru-based neurotechnology startup that featured on Shark Tank India, has raised funding from Titan Capital to expand its non-invasive neurorehabilitation platform for people living with neurological disorders such as cerebral palsy, stroke, spinal cord injury and multiple sclerosis. The investment marks xStep's entry into the Titan Capital portfolio. The investment amount remains undisclosed.

With the expansion of xStep, its non-invasive spinal neuromodulation platform, the company is helping India take an important step toward becoming a global hub for advanced neurorehabilitation.

Neurological disorders are among the leading causes of long-term disability worldwide, yet access to advanced rehabilitation remains limited, especially in emerging markets. xStep is set on changing that by making its technology more affordable and easier to reach for patients and healthcare providers.

Developed by SpineX Inc. (US) and manufactured by VIVATRONIX Tech (India), xStep combines non-invasive spinal neuromodulation with structured rehabilitation.

The funding will support commercial expansion across India, manufacturing scale-up, clinical evidence generation and regulatory work in both domestic and international markets. As part of its next phase, xStep has launched xStep One, an integrated neurorehabilitation experience centre in Bengaluru.

Through a collaboration with Trexo Robotics, it has also brought the company's wearable robotic gait trainer for children to India, making xStep One one of the first centres in the country to offer both xStep spinal neuromodulation and Trexo robotic gait training within a single integrated rehabilitation programme.

Over the next 12-24 months, xStep plans to build up its manufacturing, expand clinical collaborations in India and abroad, add to the evidence across neurological disorders, and keep developing technologies that connect neuroscience research with day-to-day patient care. It also plans to work more closely with clinicians, hospitals and rehabilitation centres so that this kind of care reaches more patients.